![]() |
Name |
Foeniculin B
|
Molecular Formula | C13H18O5 | |
IUPAC Name* |
3-(4-methoxy-5-methyl-6-oxopyran-2-yl)butylacetate
|
|
SMILES |
COc1cc(C(C)CCOC(C)=O)oc(=O)c1C
|
|
InChI |
InChI=1S/C13H18O5/c1-8(5-6-17-10(3)14)11-7-12(16-4)9(2)13(15)18-11/h7-8H,5-6H2,1-4H3/t8-/m0/s1
|
|
InChIKey |
IFUCLADIXFCVIQ-QMMMGPOBSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 254.28 | ALogp: | 2.0 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 18 | QED Weighted: | 0.756 |
Caco-2 Permeability: | -4.609 | MDCK Permeability: | 0.00004670 |
Pgp-inhibitor: | 0.398 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.007 |
30% Bioavailability (F30%): | 0.974 |
Blood-Brain-Barrier Penetration (BBB): | 0.955 | Plasma Protein Binding (PPB): | 79.50% |
Volume Distribution (VD): | 0.856 | Fu: | 33.82% |
CYP1A2-inhibitor: | 0.895 | CYP1A2-substrate: | 0.76 |
CYP2C19-inhibitor: | 0.853 | CYP2C19-substrate: | 0.704 |
CYP2C9-inhibitor: | 0.421 | CYP2C9-substrate: | 0.695 |
CYP2D6-inhibitor: | 0.014 | CYP2D6-substrate: | 0.645 |
CYP3A4-inhibitor: | 0.107 | CYP3A4-substrate: | 0.517 |
Clearance (CL): | 4.372 | Half-life (T1/2): | 0.565 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.62 |
Drug-inuced Liver Injury (DILI): | 0.803 | AMES Toxicity: | 0.028 |
Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.072 |
Skin Sensitization: | 0.341 | Carcinogencity: | 0.081 |
Eye Corrosion: | 0.043 | Eye Irritation: | 0.514 |
Respiratory Toxicity: | 0.03 |